Patent ID: 9611513
Date: 2017-04-04
CPC Classifications: C12Q,G01N

Claim:
1. A method of determining the pharmacokinetic profile of human umbilical cord tissue-derived cells in patient: a. administering a known quantity of a homogeneous population of isolated human umbilical cord tissue-derived cells of either XX or XY karyotype; b. providing a blood sample from a male or female patient that has been treated with the known quantity of human umbilical cord tissue-derived cells; c. testing the patient blood sample to detect one or more unique markers positive for the human umbilical cord tissue-derived cells and CD45; d. comparing the test results to a unique marker profile for the human umbilical cord tissue-derived cells and CD45 to distinguish between the patient peripheral blood mononuclear cells and human umbilical cord tissue-derived cells based on the detection of the unique marker profile; e. quantifying the number of human umbilical cord tissue-derived cells; and f. generating a pharmacokinetic profile for the treatment using the homogeneous population of isolated human umbilical cord tissue-derived cells, wherein the unique marker profile of the human umbilical cord tissue-derived cells comprises one or more markers positive for the human umbilical cord tissue-derived cells, wherein the unique marker profile of the human umbilical cord tissue-derived cells comprises one or more markers positive for the human umbilical cord tissue-derived cells, wherein said one or more markers positive for the human umbilical cord tissue derived cells do not comprise CD45, and wherein the human umbilical cord tissue-derived cells are isolated from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, have the potential to differentiate, and have the following characteristics: (1) express CD10, CD13, CD44, CD90, NRP1, DKK3, LAMP1, and HLA-ABC; (2) do not express CD31, CD34, HLA-DR and CD117, and (3) do not express hTERT or telomerase.